VENLO, Netherlands – QIAGEN has announced a major enhancement to its digital PCR (dPCR) portfolio, now including a suite of tools specifically designed for lentivirus-based applications in cell and gene therapy (CGT).
The new solutions provide biotech and pharmaceutical manufacturers with powerful instruments for high-precision quality control during the development and production of advanced therapies such as CAR-T — a personalised cancer immunotherapy that uses lentiviral vectors to deliver therapeutic genes into immune cells.
Why It Matters
As cell and gene therapies become more prominent in treating cancer, genetic conditions, and rare diseases, the need for reliable and scalable quality control has grown significantly. QIAGEN’s expanded dPCR offering addresses this demand with tools that help ensure safety, regulatory compliance, and consistent manufacturing outcomes.
“Cell and gene therapy developers face increasing demands for precise, scalable solutions to help ensure therapy safety and efficacy,” said Justus Krause-Harder, Vice President of Molecular Tools & Oncology at QIAGEN. “With our expanded dPCR portfolio, we are reaffirming our commitment to supporting biopharma innovation.”
New Tools Included
Here are some highlights of QIAGEN’s updated workflow:
- QIAcuity RCL Quant Kit
Detects replication-competent lentiviruses (RCL) — a key safety requirement in lentiviral vector production. - CGT dPCR Assays
Includes 8 validated lentiviral targets for titration and vector copy number (VCN) determination. Enables both singleplex and multiplex workflows. - CGT Lentivirus Lysis Kit
Reduces hands-on steps and enhances accuracy in viral genome titer quantification.
Combined with QIAcuity nanoplates and master mixes, these tools offer absolute quantification for viral particles and gene insertions — fundamental parameters in drug development and manufacturing.
Beyond Lentivirus
The expanded portfolio also includes:
- Residual DNA quantification kits for common cell lines (HEK293, CHO, E. coli)
- Mycoplasma detection
- AAV vector assays
- Viral vector integrity testing tools
These innovations position QIAGEN as a key partner in supporting biotherapeutic developers through evolving industry regulations and production demands.
Visit QIAGEN’s Cell and Gene Therapy Solutions for full details.
Español de Chile 
English (UK)